Join this interactive roundtable to explore how the field can move beyond a one-size-fits-all approach and embed precision medicine into IPF drug development.

Discussion Points:

• How are we currently defining and addressing biological and clinical heterogeneity in IPF, and where are the gaps?
• What role can blood-based, molecular, and digital biomarkers play in identifying responders and reducing -clinical trial variability?
• How can biomarker strategies be more effectively integrated across the pipeline, from early discovery through to late-stage development?
• What are the key barriers to implementing precision approaches in IPF today, and how can the field overcome them?